Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 15/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 12/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26205861 | 0.97 | ADRB2 (0.40) | ADRB2HTR1AADRB1PPARGMAPT | |
| SCHEMBL26206391 | 0.89 | LTB4R (0.44) | ADRB2ADRB1 | |
| SCHEMBL27015526 | 0.89 | LTB4R (0.44) | ADRB2ADRB1 | |
| SCHEMBL27015244 | 0.88 | ADRB2 (0.37) | ADRB2ADRB1MTNR1A | |
| SCHEMBL27015423 | 0.88 | ADRB2 (0.39) | ADRB2HTR1AADRB1PPARGHDAC1 | |
| SCHEMBL27015257 | 0.87 | ADRB2 (0.39) | ADRB2ADRB1 | |
| SCHEMBL27015403 | 0.87 | ADRB2 (0.39) | ADRB2HTR1AADRB1PPARGHDAC1 | |
| SCHEMBL26206390 | 0.86 | LTB4R (0.40) | ADRB2ADRB1MTNR1A | |
| SCHEMBL23833191 | 0.82 | AAK1 (0.39) | ADRB2HTR1AADRB1HDAC1HDAC6 | |
| SCHEMBL22526125 | 0.82 | AAK1 (0.39) | ADRB2HTR1AADRB1HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | ADRB2 4571/4885HTR1A 3834/4885ADRB1 4560/4885 |
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | ADRB2 4571/4885HTR1A 3834/4885ADRB1 4560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.